Connect with us

Technology

Respected pharma data science pioneer Dr Ben Sidders to spearhead Biorelate’s next growth phase as Chief Scientific Officer

Published

2 weeks ago

on

* Dr Sidders brings two decades of deep data science experience, honed across multiple therapeutic areas at Pfizer and AstraZeneca * He will build on Biorelate’s strong track record of leveraging advanced data science methods to extract critical knowledge from vast amounts of biomedical literature * These new data-derived insights are enabling drug developers to identify new targets with maximum market potential.

MANCHESTER, England, Sept. 5, 2024 /PRNewswire-PRWeb/ — Biorelate has announced the appointment of leading pharmaceutical industry data science expert, Dr Ben Sidders, as Chief Scientific Officer. Formerly Executive Director, Head of Early Data Science at AstraZeneca within Oncology R&D, Dr Sidders will spearhead a new growth phase for Biorelate, which leverages advanced data science methods to transform the focus and impact of drug discovery and development.

This prestigious appointment is an important endorsement of the great work we are doing, and we are delighted to welcome Ben on board. His scientific direction will give Biorelate an even deeper footing within modern drug discovery and development.

Dr Sidders has spent two decades leading data science teams at both AstraZeneca and Pfizer, to pioneer and apply novel data science methods for drug discovery in oncology, neuroscience and infectious disease.

Biorelate specialises in advanced data science methods for drug discovery to deliver robust, evidence-based intelligence to those making critical decisions about the next drugs to take forward. The actionable insights it distils, from across diverse ‘dark’ (previously unsearchable) knowledge assets and existing texts, ensure that investment is concentrated on the targets most likely to succeed in drug development – with a positive impact for patients, while delivering financially for the drug developer and its backers.

Dr Sidders, who has followed Biorelate closely since the company’s foundation in 2014, believes the company is at an important inflection point thanks to its proven technology and a significant opportunity to grow and scale. That’s as drug developers look to next-generation data science to transform their early research, and improve new drug candidates’ probability of success.

Of the opportunity Biorelate addresses, Dr Sidders said: “The pharmaceutical industry is rapidly adopting data science-driven approaches using artificial intelligence. This has meant a shift away from the traditional pharma R&D model (very low throughput, with heavy reliance on academic literature to determine new targets), towards an Artificial Intelligence (AI)-first approach.

“The risk with this approach is that researchers do not really understand the causality of their findings, which is critical if you want to develop a successful drug. Biorelate fills that gap by drawing on a wealth of data to develop causal models and explaining – mechanistically and in the appropriate context – what the next opportunities are and why. Crucially, Biorelate’s technology platform has causality built in – something that’s lacking in other AI approaches to drug discovery. It has proven adept at finding new targets, and has promise in other areas of the pipeline too, from biomarker discovery and patient stratification to the identification of promising drug combinations. This is a really exciting time for Biorelate, and for data science in drug discovery more broadly.”

Daniel Jamieson, Biorelate’s CEO, said: “This prestigious appointment is an important endorsement of the great work we are doing, and we are delighted to welcome Ben on board. His scientific direction will give Biorelate an even deeper footing within modern drug discovery and development.

“At AstraZeneca, Ben’s team was responsible for delivering data-driven, actionable insights to all parts of the company’s oncology portfolio, including advancing the understanding of disease. His years at Pfizer, and his extensive experience of all facets of drug discovery across major pharma, add richly to his understanding of what the industry needs now to transform R&D performance – insights and expertise we can now extend to our diverse client base.”

Dr Sidders’ personal fields of interest include immuno-oncology, network biology and the role of bioinformatics within drug discovery. He has a PhD in Molecular Biology & Bioinformatics from the University of London where his thesis focused on the development of predictive markers for the diagnosis of asymptomatic Tuberculosis. Ben holds patents for two clinical diagnostics and has authored over 30 scientific publications.

About Biorelate

Biorelate is a world leader in leveraging advanced data science methods to extract critical knowledge from vast amounts of pharmaceutical data and literature, significantly enhancing the discovery of novel biopharmaceuticals. Biorelate offers multiple product lines powered by its proprietary platform, Galactic AI™.

Galactic AI™ employs sophisticated natural language processing (NLP) and artificial intelligence (AI) to uncover hidden cause- and-effect relationships. This innovative platform provides unprecedented insights into disease pathways, enabling more precise and effective drug discovery. As the incredible progress of scientific researchers continues to compound the huge volume of growing and evolving biomedical data, Biorelate’s mission to curate knowledge to advance the world’s most promising biomedical innovations has never been so important.

Media Contact

Mira Nair, Biorelate, 44 07799153550, mira.nair@biorelate.com, https://biorelate.com/

View original content to download multimedia:https://www.prweb.com/releases/respected-pharma-data-science-pioneer-dr-ben-sidders-to-spearhead-biorelates-next-growth-phase-as-chief-scientific-officer-302239087.html

SOURCE Biorelate

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Dana-Farber Cancer Institute Partners with Clinical.ly to Enhance Regulatory Operations with eReg Solutions

Published

2 mins ago

on

September 19, 2024

By

NEW YORK, Sept. 19, 2024 /PRNewswire/ — The Dana-Farber Cancer Institute, a world leader in cancer treatment and research, chose Clinical.ly’s (www.clinical.ly) Research Suite™ to streamline regulatory operations, marking a significant step toward more efficient and compliant clinical trial management. Dana-Farber joins a growing number of research organizations that leverage Clinical.ly’s innovative solutions to streamline clinical trial processes. Clinical.ly’s eReg platform offers a comprehensive, paperless solution that centralizes regulatory workflows, ensuring compliance and transparency across clinical trials.

“We are thrilled to support Dana-Farber’s clinical research operations,” said Henry Kravchenko, Clinical.ly’s CEO.

This partnership continues Clinical.ly’s success in providing best-in-class enterprise tools for conducting clinical research. “We are thrilled to support Dana-Farber’s clinical research operations,” said Henry Kravchenko, Clinical.ly’s CEO. “Our eReg platform and wider set of features in Clinical.ly Research Suite™ will empower that renowned organization, and we all look forward to supporting their teams.”

About Clinical.ly Research Suite™ 

Clinical.ly Research Suite™ is a comprehensive solution that eliminates traditional, paper-based processes. By automating and centralizing essential workflows in the Clinical.ly Research Suite™, organizations achieve huge efficiency improvements, greater trial oversight, document management, and regulatory compliance. The Clinical.ly Research Suite™ includes:

eReg: A best-in-class electronic regulatory bindereSource: An intuitive & feature-rich, paperless data capture solution that streamlines data collection from trial participantseConsent: A fully digital solution for capturing informed consent, improving participant engagement and site complianceClinicallySign: 21 CFR Part 11 compliant eSignature functionalityClinicallyPay: A secure and instantaneous participant stipend payment and reimbursement solution

About Dana-Farber Cancer Institute

Founded in 1947, Dana-Farber Cancer Institute is committed to providing adults and children with the best treatment available today while developing tomorrow’s cures through cutting-edge research. Based in Boston, Dana-Farber is a teaching affiliate of Harvard Medical School and ranks consistently as one of the top cancer hospitals in the world.

About Clinical.ly

Clinical.ly provides differentiated, cloud-native technology solutions to the clinical research industry, enabling research organizations to conduct studies with greater efficiency and ease. Clinical.ly is dedicated to developing technology that eliminates tedious manual labor, allowing clinical research professionals to focus on patient care.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dana-farber-cancer-institute-partners-with-clinically-to-enhance-regulatory-operations-with-ereg-solutions-302253690.html

SOURCE Clinical.ly

Continue Reading

Technology

Fall Into Creativity with the Monport Laser Fall Sale

Published

2 mins ago

on

September 19, 2024

By

NEW YORK, Sept. 19, 2024 /PRNewswire/ — Experience laser innovation this Fall with Monport Laser, an industry frontrunner in laser engraving and cutting technology, with an exclusive Fall Sale offering incredible discounts and free accessories on a wide range of high-performance laser engraving machines. From September 19th to September 30th, customers can take advantage of this limited-time opportunity to elevate their laser engraving businesses with cutting-edge laser innovation at unbeatable prices.

Monport Laser has been dedicated to providing innovative and reliable laser machines that empower businesses and individuals to achieve their goals. With a focus on quality, precision, and customer satisfaction, Monport Laser has established itself as a trusted leader in the industry. Their commitment to excellence is evident in every laser they produce, ensuring exceptional performance, reliability, and value.

Embrace the Power of CO2 Laser Technology with Exclusive Offers

Monport Laser will offer two free accessories with selected CO2 laser machines during the Monport Fall sale. These versatile lasers are ideal for various applications, including engraving, cutting, and marking wood, acrylic, leather, and more. By taking advantage of this Fall sale, laser engraving businesses can enhance their productivity and expand their creative possibilities.

Experience Unmatched Value with Fiber Laser Discounts

Monport Laser offers substantial discounts of up to $4200 and 3 free accessories on selected models for those seeking the precision and speed of fiber laser technology. Fiber lasers are renowned for their ability to process metals with exceptional efficiency and accuracy, making them indispensable for metal fabrication, manufacturing, and jewelry production. Additionally, customers purchasing fiber lasers during the Fall sale will receive three free accessories, further sweetening the deal.

Elevate Your Desktop Laser Experience with a Free Water Chiller

Monport Laser is committed to providing comprehensive solutions for businesses of all sizes. As part of the Fall sale, customers who purchase the 40W Desktop laser will receive a Free Water Chiller Cw3000. This essential accessory ensures optimal cooling and performance, prolonging the lifespan of the laser and guaranteeing consistent results.

Discover Additional Savings on a Wide Range of Accessories

Monport Laser offers an additional 20% discount on selected accessories to complete your laser setup. From lenses and nozzles to rotary tables and smoke extraction systems, customers can find everything they need to maximize the potential of their laser machines.

Unleash Your Creativity and Productivity

Monport Laser’s Fall sale is the perfect opportunity to invest in laser technology that empowers your business or fuels your creative passions. With exceptional discounts and free accessories, you can acquire the ideal laser solution to meet your needs and budget.

Whether you’re an entrepreneur, artist, or manufacturer, Monport Laser’s advanced laser machines offer unparalleled precision, versatility, and reliability. Take advantage of this limited-time Fall sale and unlock your projects’ full potential for laser innovation.

About Monport Laser

Monport Laser is a global leader in designing, manufacturing, and distributing high-quality laser machines and accessories. With a commitment to innovation and customer satisfaction, Monport Laser provides cutting-edge solutions for various industries, including manufacturing, engraving, marking, and more.

For more information, visit monportlaser.com and follow them on social media for the latest updates.

Website: https://www.monportlaser.com/

 

 

 

View original content:https://www.prnewswire.com/news-releases/fall-into-creativity-with-the-monport-laser-fall-sale-302253699.html

SOURCE Monport Laser

Continue Reading

Technology

MEDIA ADVISORY – Minister Wilkinson to Make a Critical Minerals Infrastructure Announcement

Published

2 mins ago

on

September 19, 2024

By

VANCOUVER, BC, Sept. 19, 2024 /CNW/ – The Honourable Jonathan Wilkinson, Minister of Energy and Natural Resources, and Ranj Pillai, the Premier of Yukon, will make a funding announcement in support of critical minerals infrastructure projects. A media availability will follow.

Date: September 20, 2024

Time: 10:30 a.m. PT

All accredited media are asked to pre-register by emailing media@nrcan-rncan.gc.ca. A dial-in line is available for media and will be provided upon registration.

Follow us on LinkedIn

SOURCE Natural Resources Canada

Continue Reading

Trending